Table 4.
Preclinical development of CD16 antigen based bispecific antibodies targeting solid tumors.
| Bispecific antibody | Target malignancy | References |
|---|---|---|
| Anti-MOV19-AntiCD16 | Ovarian cancer | Ferrini et al. (209) |
| Anti-ovarian carcinoma(IgG2a)-AntiCD16 | Ovarian cancer | Ferrini et al. (210) |
| Anti-NCAM -AntiCD16 | Human glioma | Obukhov et al. (211) |
| Anti-CA19-9- AntiCD16 | Colorectal adenocarcinoma | Garcia de Palazzo et al. (212) |
| Anti-c-erbB-2-Anti CD16 | Ovarian cancer | Weiner et al. (213) |
| Anti-FBP-Anti CD16 | Ovarian cancer | Ferrini et al. (214) |
| Anti-c-erbB-2-Anti FcgammaRIII | c-ERB-2 positive tumors | Weiner et al. (215) |
| Anti-c-erbB-2-Anti FcgammaRIII | Ovarian adenocarcinoma | Weiner et al. (216) |
| Anti-HER2/neu- AntiFcgammaRIII | Ovarian adenocarcinoma | McCall et al. (217) |
| Anti-PDGFR- AntiFcgammaRIII | Lung cancer | Gruel et al. (218) |
| Trivalent anti-erbB2-anti-CD16 | Breast cancer | Xie et al. (219) |
| Anti-HER2/neu-Anti CD16 minibody | Ovarian cancer | Shahied et al. (220) |
| Anti-ErbB2-Anti-CD16 | Breast cancer | Lu et al. (202) |
| Anti-EGFR-Anti-CD16 | Cholangiocarcinoma | Asano et al. (221) |
| Anti-EpCAM-Anti-CD16 | Prostate, breast, colon, head and neck cancer | Vallera et al. (206) |
| Anti-HER2-Anti- FcγRIIIA | Breast cancer | Turini et al. (205) |
| Anti-CD133-Anti-CD16 | Colorectal cancer | Schmohl et al. (222) |
| Anti-CEA and Anti-CD16 | Ovarian and colorectal cancer | Dong et al. (223) |
| Anti-EpCAM-IL-15 crosslinker-Anti-CD16 (TriKE) | Colorectal cancer | Schmohl et al. (208) |
| Anti-EpCAM-AntiCD133-IL-15 crosslinker-Anti-CD16 (TetraKE) | Colorectal cancer | Schmohl et al. (224) |
| AntiCD133-IL-15 crosslinker-Anti-CD16 (TriKE) | Colorectal cancer | Schmohl et al. (225) |
| Anti-Muc1-Anti-CD16 | Colorectal, ovarian and lung cancer | Li et al. (226) |
| Anti-(HER2)2-Anti-CD16 Tribody | Pancreatic, ovarian, esophageal cancer | Oberg et al. (207) |
| Anti-GPC3-Anti-CD16 | Liver carcinoma | Wang et al. (227) |